IDEAYA Biosciences (IDYA) Return on Capital Employed (2019 - 2026)
IDEAYA Biosciences (IDYA) posted Return on Capital Employed of 18.26% for Q1 2026, down 24.72% sequentially from 14.64% in Q4 2025, and up 1569.0% YoY from 1.09% in Q1 2025.
IDEAYA Biosciences (IDYA) Return on Capital Employed (2019 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Return on Capital Employed for 8 years, with the latest figure at 18.26% in Q1 2026.
- Quarterly Return on Capital Employed rose 1569.0% year-over-year to 18.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18.26% (up 1569.0% YoY) and the FY2025 annual result came in at 15.06%, up 2384.0% from the prior year.
- Return on Capital Employed retreated to 18.26% in Q1 2026 per IDYA's latest filing, from 14.64% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 14.64% in Q4 2025 and troughed at 37.83% in Q2 2025.
- A 5-year average of 22.24% and a median of 20.65% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 1718 bps in 2025, then surged 1569 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 17.0% in 2022, then sank by 40 bps to 23.83% in 2023, then declined by 21 bps to 28.79% in 2024, then jumped by 49 bps to 14.64% in 2025, then slipped by 25 bps to 18.26% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 18.26%, 14.64%, and 19.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | -19.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.95% |
| Mar 31, 2026 | -18.26% |
| Dec 31, 2025 | -14.64% |
| Sep 30, 2025 | -19.92% |
| Jun 30, 2025 | -37.83% |
| Mar 31, 2025 | -33.95% |
| Dec 31, 2024 | -28.79% |
| Sep 30, 2024 | -21.08% |
| Jun 30, 2024 | -20.65% |
| Mar 31, 2024 | -20.39% |
| Dec 31, 2023 | -23.83% |
| Sep 30, 2023 | -23.54% |
| Jun 30, 2023 | -20.14% |
| Mar 31, 2023 | -21.52% |
| Dec 31, 2022 | -17.00% |
| Sep 30, 2022 | -15.93% |
| Jun 30, 2022 | -23.01% |
| Mar 31, 2022 | -17.68% |
| Dec 31, 2021 | -14.56% |
| Sep 30, 2021 | -11.43% |